Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A craniosynostosis that is part of a larger syndrome.
No HPO annotations are available for this condition.
Age of onset: at birth, newborn period.
Individuals with achondroplasia have short stature with rhizomelic shortening of the limbs, macrocephaly, characteristic facies with frontal bossing and midface retrusion, exaggerated lumbar lordosis, limitation of elbow extension and rotation, genu varum, brachydactyly, and trident appearance of the hands. Excess mobility of the knees, hips, and most other joints is common . Growth. Average adult height for men with achondroplasia is 129.9 ± 6.25 cm (51 inches) and for women, 122.4 ± 5.9 cm (48 inches). There are updated growth charts available for length, weight, head circumference, and height-to-weight ratio . Vosoritide, a C-type natriuretic peptide (CNP) analog, was approved to increase height in individuals with achondroplasia starting at birth. Studies showed an average of 1.
The clinical and radiologic features that can establish the diagnosis of achondroplasia have been well defined .
The diagnosis of achondroplasia should be suspected in a newborn with the following clinical features; characteristic radiographic features can confirm the diagnosis.
• Clinical features in a newborn
Proximal shortening of the arms
No approved treatments are currently available for syndromic craniosynostosis. The disease remains an area of unmet medical need.
Gene therapy approaches for syndromic craniosynostosis have been reported in the published literature.
Recommendations for health supervision of children with achondroplasia were outlined by the American Academy of Pediatrics Committee on Genetics . These recommendations serve as guidelines and do not replace individual decision making. The review by also provides management recommendations. Specialized skeletal dysplasia clinics exist; their recommendations may vary slightly from these general guidelines. Evaluations Following Initial Diagnosis Clinical manifestations in achondroplasia vary modestly. In order to establish the extent of disease in an individual diagnosed with achondroplasia, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Achondroplasia: Recommended Evaluations Following Initial Diagnosis
Recommendations for surveillance are incorporated into the American Academy of Pediatrics guidelines . To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 7. Achondroplasia: Recommended Surveillance
No clinical trials have been registered for syndromic craniosynostosis.
207 publications have been identified in PubMed for syndromic craniosynostosis. Kisho has analyzed 93 by research type. Research spans Epidemiology / Natural History (32%), Clinical Trial Publication (22%), and Review / Meta-Analysis (19%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 30 | 32% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 3:46 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Source: GeneReviews — "Achondroplasia"
Large head
Narrow chest
Short fingers with a trident configuration
• Radiographic features in a newborn that can establish the diagnosis
Square ilia and horizontal acetabula
Narrow sacrosciatic notch
Proximal radiolucency of the femurs
Generalized metaphyseal abnormality including flaring
Decreasing interpedicular distance caudally
Source: GeneReviews — "Achondroplasia"
While more than 700 skeletal dysplasias are recognized , many are extremely rare, and virtually all have clinical and radiographic features that readily distinguish them from achondroplasia. Conditions that may be confused with achondroplasia are listed in .
Table 3.
Achondroplasia: Differential Diagnosis
Gene(s) | Disorder | MOI | Clinical Characteristics
| Hypochondroplasia | AD | See .
Severe achondroplasia w/developmental delay acanthosis nigricans (SADDAN) (OMIM 616482)
Thanatophoric dysplasia
Source: GeneReviews — "Achondroplasia"
Biomarker and diagnostic research for syndromic craniosynostosis has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Growth | Documentation of length, weight, head circumference compared w/achondroplasia-specific growth standards | — |
Hydrocephalus | Brain imaging as soon after diagnosis as possible to assess ventricular size | Neurologic/ Musculoskeletal |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention Restrictive pulmonary disease |
Obstructive sleep apnea (OSA) | If polysomnography shows OSA, referral to ENT | Significant OSA can occur w/craniocervical junction stenosis given that it may worsen hypotonia. MRI of craniocervical junction should be obtained in newborn period. |
Hearing | Audiologic eval | — |
Genetic counseling | By genetics professionals3 | To obtain a pedigree inform affected persons their families re nature, MOI, implications of achondroplasia to facilitate medical personal decision making Family support |
resources | By clinicians, wider care team, family support organizations | Assessment of family social structure to determine need for:; Community or; Social work involvement for parental support AFMS = Achondroplasia Foramen Magnum Score; ENT = otolaryngology; MOI = mode of inheritance; OSA = obstructive sleep apnea; SD = standard deviation 1. 2. |
Achondroplasia: Targeted Therapy Treatment | Dosage | Consideration |
Vosoritide(C-type natriuretic peptide analog) | 15-30 g/kg subcutaneously daily depending on age | To height in children w/achondroplasia until growth plates close1; Injections should be given after a meal drinking 8-12 oz of fluids to minimize hypotension. In younger children, give after a feeding. Phase III studies showed an increase in annualized growth velocity of 1. |
Source: GeneReviews — "Achondroplasia"
View trials for syndromic craniosynostosis
System/Concern
Evaluation |
|---|
Frequency |
|---|
General | Consider eval w/geneticist or other provider experienced in care of persons w/bone dysplasias. | At least every 6 mos in infants toddlers, annually in children, every 5 yrs in adults |
Growth | Monitor height weight using growth curves standardized for achondroplasia.1 | At each visit Obesity |
Head growth/ Hydrocephalus | Measure occipitofrontal circumference use charts standardized for achondroplasia.5 | At every visit until age ~6 yrs then throughout childhood at well checks clinical genetics visits |
Narrow craniocervical junction | Neurologic exam incl monitoring for signs of cervical myelopathy such as persistent hypotonia, hyperreflexia, clonus, asymmetries on neurologic exam or w/function | At every visit in infancy childhood Development |
Restrictive pulmonary disease | Assess for persistent tachypnea, poor weight gain, or evidence of respiratory failure. | At each visit throughout infancy |
Source: GeneReviews — "Achondroplasia"
Clinical study results |
20 |
22% |
Research summaries | 18 | 19% |
Patient case studies | 9 | 10% |
Testing and diagnosis research | 6 | 6% |
Laboratory research | 5 | 5% |
New treatment approaches | 3 | 3% |
Other research | 2 | 2% |
Moreno-Villagómez J (2026). [PMID: 41820702](https://pubmed.ncbi.nlm.nih.gov/41820702/). *Childs Nerv Syst*. [Case Report / Case Series]
Chaisrisawadisuk S (2026). [PMID: 41609211](https://pubmed.ncbi.nlm.nih.gov/41609211/). *J Craniofac Surg*. [Case Report / Case Series]
Onur H (2026). [PMID: 42084887](https://pubmed.ncbi.nlm.nih.gov/42084887/). *Turk Arch Pediatr*. [Basic Science / Preclinical]
Rufai SR (2026). [PMID: 41735680](https://pubmed.ncbi.nlm.nih.gov/41735680/). *Eye (Lond)*. [Diagnostic / Biomarker]
Fussell RA (2026). [PMID: 42130417](https://pubmed.ncbi.nlm.nih.gov/42130417/). *J Craniofac Surg*. [Diagnostic / Biomarker]
Delassus O (2026). [PMID: 40624761](https://pubmed.ncbi.nlm.nih.gov/40624761/). *J Anat*. [Clinical Trial Publication]
Garcia-Usó M (2026). [PMID: 41004638](https://pubmed.ncbi.nlm.nih.gov/41004638/). *Cleft Palate Craniofac J*. [Epidemiology / Natural History]
Chen S (2026). [PMID: 42158648](https://pubmed.ncbi.nlm.nih.gov/42158648/). *Transl Pediatr*. [Epidemiology / Natural History]
Park RK (2026). [PMID: 41637834](https://pubmed.ncbi.nlm.nih.gov/41637834/). *Int J Pediatr Otorhinolaryngol*. [Epidemiology / Natural History]
Guillen Arguello R (2026). [PMID: 40693761](https://pubmed.ncbi.nlm.nih.gov/40693761/). *Oper Neurosurg*. [Case Report / Case Series]